Lexicon Completes Enrollment in Phase 3 HCM Trial Ahead of Schedule — Lexicon Pharmaceuticals, Inc.

Event summary

Lexicon Pharmaceuticals completed enrollment in its Phase 3 SONATA-HCM trial for sotagliflozin, exceeding the target of 500 patients across 130+ sites in 20 countries.
The study includes a substantial majority of non-obstructive HCM patients, with topline results expected in Q1 2027.
SONATA-HCM is the largest Phase 3 trial to date for both non-obstructive and obstructive HCM.
Sotagliflozin is a dual SGLT1/SGLT2 inhibitor studied in over 20,000 patients across heart failure, diabetes, and chronic kidney disease.

The big picture

Lexicon's accelerated enrollment in the SONATA-HCM trial highlights growing interest in targeted therapies for hypertrophic cardiomyopathy, a condition with significant unmet medical need. The study's focus on both obstructive and non-obstructive forms positions sotagliflozin as a potential first-in-class treatment, though competition remains intense in the cardiometabolic space.

What we're watching

Clinical Efficacy: Whether sotagliflozin demonstrates meaningful symptom improvement in HCM patients, as measured by the KCCQ CSS score.
Regulatory Pathway: The pace at which Lexicon can advance sotagliflozin through regulatory approvals if Phase 3 results are positive.
Market Differentiation: How Lexicon positions sotagliflozin against existing HCM therapies, particularly for non-obstructive HCM where treatment options are limited.